Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 3Phase 1/2 2Phase 2/3 1

Status

Recruiting 5Active not recruiting 3Completed 1

Sponsor Class

INDUSTRY 9OTHER 7NETWORK 1

Study Type

Interventional 9

Sponsor

Cancer Type

Breast 8Gastrointestinal 2

Conditions

Breast Neoplasms 5HER2-positive Breast Cancer 2Triple Negative Breast Neoplasms 1Stomach Neoplasms 1HER2-positive Metastatic Breast Cancer 1Colorectal Neoplasms 1

Interventions

pembrolizumab 279Carboplatin 214Cisplatin 145Gemcitabine 144Paclitaxel 142Bevacizumab 115Pemetrexed 112Docetaxel 100Oxaliplatin 78Dexamethasone 77durvalumab 76Fluorouracil 76atezolizumab 75Nivolumab 74Cyclophosphamide 74130-nm albumin-bound paclitaxel 71Fulvestrant 68Cetuximab 63Capecitabine 63Injections 61Leucovorin 60Rituximab 55fludarabine 50Lenalidomide 49venetoclax 43Prednisone 43Irinotecan 42enzalutamide 39Letrozole 39tislelizumab 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

9 trials
RecentStart dateEnrollment
INDUSTRY × tucatinib × 90 days × Clear all
NCT05253651 2026-06-04

MOUNTAINEER-03

Seagen Inc.

Phase 3 Recruiting
400 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT06686394 2026-05-22

MK-1022-009

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
81 enrolled
Breast

Breast Neoplasms

NCT07413939 2026-05-11

BREnnA

Hoffmann-La Roche

Phase 2/3 Recruiting
650 enrolled
Breast

HER2-positive Breast Cancer

NCT06157892 2026-05-05

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

Seagen Inc.

Phase 2 Recruiting
172 enrolled
BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT05132582 2026-04-20

HER2CLIMB-05

Seagen Inc.

Phase 3 Active not recruiting
654 enrolled
Breast

Breast Neoplasms

NCT05458674 2026-04-03

Tucatinib+Trastuzumab+Eribulin in HER2+ MBC

Criterium, Inc.

Phase 2 Recruiting
30 enrolled
Breast

Breast Neoplasms

NCT03975647 2026-03-30

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

Seagen Inc.

Phase 3 Active not recruiting
466 enrolled 17 charts
Breast

HER2-positive Breast Cancer

NCT04539938 2026-03-23

HER2CLIMB-04

Seagen Inc.

Phase 2 Completed
70 enrolled 23 charts
Breast

Breast Neoplasms

NCT05230810 2026-03-16

Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.

Criterium, Inc.

Phase 1/2 Active not recruiting
40 enrolled
Breast

HER2-positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡